Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma

Kiran K. Turaga, Susan Tsai, Lauren A. Wiebe, Douglas B. Evans, T. Clark Gamblin

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Neoadjuvant chemoradiation has demonstrated significant advantages in the management of pancreatic adenocarcinoma. A similar tumor in a nearby anatomical location is extrahepatic cholangiocarcinoma, which has proven to be largely unresponsive to current forms of therapy. Neoadjuvant therapy for hilar cholangiocarcinoma has been combined with surgical resection and/or liver transplantation with a 25-33 % complete pathological response rate. We propose a wider application of neoadjuvant chemoradiation for patients with distal cholangiocarcinoma and present our rationale for this form of treatment sequencing.

Original languageEnglish (US)
Pages (from-to)1230-1239
Number of pages10
JournalAnnals of Surgical Oncology
Issue number4
StatePublished - Apr 1 2013

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this